跳至主要内容
临床试验/NCT03525665
NCT03525665已完成不适用

Study on the Role of FDG-PET in Patients With Follicular Lymphoma at Time of Relapse/Progression

Fondazione Italiana Linfomi - ETS27 个研究点 分布在 1 个国家目标入组 175 人开始时间: 2016年5月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
175
试验地点
27
主要终点
PFS

研究概览

简要总结

The study is designed as a retrospective analysis of patients with relapsed/refractory FL identified by the hematological centers of Italy.

详细描述

The study does not require any intervention on the patient, but it involves the simple collection of data that are already present in the medical record. Since this is a retrospective study, it will not require further analysis or diagnostic investigations than those already made.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with initial diagnosis of follicular lymphoma since 2001
  • Histological confirmation of follicular lymphoma, grade I, II, III according to WHO 2008 classification, at the time of initial diagnosis
  • Systemic first-line treatment with immuno-chemotherapy
  • PET availability at the time of response after first-line treatment (optional)
  • Clinical and radiological evidence of FL relapse or progression
  • Histological confirmation of relapse (strongly recommended)
  • PET availability of at the time of relapse/progression and images available for central assessment
  • Availability of clinical, laboratory and therapeutic treatment data at the time of initial diagnosis and relapse/progression
  • Follow up of at least 12 months after relapse/progression

排除标准

  • 未提供

结局指标

主要结局

PFS

时间窗: 24 months

Progression free survival from time of relapse/progression

次要结局

  • OS(24 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (27)

Loading locations...

相似试验